194 related articles for article (PubMed ID: 11433397)
41. Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice.
Nagaike K; Kawaguchi M; Takeda N; Fukushima T; Sawaguchi A; Kohama K; Setoyama M; Kataoka H
Am J Pathol; 2008 Nov; 173(5):1464-75. PubMed ID: 18832587
[TBL] [Abstract][Full Text] [Related]
42. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
[TBL] [Abstract][Full Text] [Related]
43. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
44. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
45. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
46. Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase.
Larsen BR; Steffensen SD; Nielsen NV; Friis S; Godiksen S; Bornholdt J; Soendergaard C; Nonboe AW; Andersen MN; Poulsen SS; Szabo R; Bugge TH; Lin CY; Skovbjerg H; Jensen JK; Vogel LK
Exp Cell Res; 2013 Apr; 319(6):918-29. PubMed ID: 23333561
[TBL] [Abstract][Full Text] [Related]
47. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration.
Camby I; Belot N; Rorive S; Lefranc F; Maurage CA; Lahm H; Kaltner H; Hadari Y; Ruchoux MM; Brotchi J; Zick Y; Salmon I; Gabius HJ; Kiss R
Brain Pathol; 2001 Jan; 11(1):12-26. PubMed ID: 11145198
[TBL] [Abstract][Full Text] [Related]
48. Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.
Náger M; Santacana M; Bhardwaj D; Valls J; Ferrer I; Nogués P; Cantí C; Herreros J
Cell Cycle; 2015; 14(22):3644-55. PubMed ID: 26654598
[TBL] [Abstract][Full Text] [Related]
49. Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin.
Fan B; Wu TD; Li W; Kirchhofer D
J Biol Chem; 2005 Oct; 280(41):34513-20. PubMed ID: 16103126
[TBL] [Abstract][Full Text] [Related]
50. High mobility group I-C protein in astrocytoma and glioblastoma.
Akai T; Ueda Y; Sasagawa Y; Hamada T; Date T; Katsuda S; Iizuka H; Okada Y; Chada K
Pathol Res Pract; 2004; 200(9):619-24. PubMed ID: 15497774
[TBL] [Abstract][Full Text] [Related]
51. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
52. Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells.
Kohama K; Kawaguchi M; Fukushima T; Lin CY; Kataoka H
Hum Cell; 2012 Dec; 25(4):100-10. PubMed ID: 23248048
[TBL] [Abstract][Full Text] [Related]
53. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP.
Hamasuna R; Kataoka H; Moriyama T; Itoh H; Seiki M; Koono M
Int J Cancer; 1999 Jul; 82(2):274-81. PubMed ID: 10389763
[TBL] [Abstract][Full Text] [Related]
54. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
55. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion.
Konduri SD; Rao CN; Chandrasekar N; Tasiou A; Mohanam S; Kin Y; Lakka SS; Dinh D; Olivero WC; Gujrati M; Foster DC; Kisiel W; Rao JS
Oncogene; 2001 Oct; 20(47):6938-45. PubMed ID: 11687973
[TBL] [Abstract][Full Text] [Related]
56. Isolation of a natural inhibitor of human malignant glial cell invasion: inter alpha-trypsin inhibitor heavy chain 2.
Werbowetski-Ogilvie TE; Agar NY; Waldkircher de Oliveira RM; Faury D; Antel JP; Jabado N; Del Maestro RF
Cancer Res; 2006 Feb; 66(3):1464-72. PubMed ID: 16452202
[TBL] [Abstract][Full Text] [Related]
57. Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2.
Maurer E; Gütschow M; Stirnberg M
Biochem J; 2013 Mar; 450(3):583-93. PubMed ID: 23293962
[TBL] [Abstract][Full Text] [Related]
58. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor.
Kodama T; Ikeda E; Okada A; Ohtsuka T; Shimoda M; Shiomi T; Yoshida K; Nakada M; Ohuchi E; Okada Y
Am J Pathol; 2004 Nov; 165(5):1743-53. PubMed ID: 15509542
[TBL] [Abstract][Full Text] [Related]
59. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of hepatocyte growth factor activator inhibitor expression in normal and malignant colonic mucosa.
Kataoka H; Uchino H; Denda K; Kitamura N; Itoh H; Tsubouchi H; Nabeshima K; Koono M
Cancer Lett; 1998 Jun; 128(2):219-27. PubMed ID: 9683286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
